Soldevir Tablet contains a combination of Ledipasvir 90mg and Sofosbuvir 400mg, a highly effective direct-acting antiviral (DAA) formulation indicated for the management of Hepatitis C infection. It helps in suppressing viral replication, reducing viral load, and supporting liver function.
The combination works by inhibiting HCV NS5A and NS5B polymerase, providing comprehensive viral suppression and aiding in the achievement of sustained virologic response (SVR). Regular therapy with Soldevir Tablet contributes to improved liver health and long-term disease control.
For distributors and healthcare suppliers, Soldevir Tablet is a high-demand antiviral product, widely prescribed in hospitals, specialty liver clinics, and gastroenterology centers. The increasing prevalence of Hepatitis C and the need for potent combination therapies ensure consistent year-round demand.
Adding Soldevir Tablet to your hepatoprotective and antiviral segment offers excellent opportunities in pharmacies, hospitals, liver care clinics, export markets, and third-party manufacturing. Its clinically proven efficacy, patient acceptance, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.